Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (26853)	12/11/1998 2:45:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

As part of the LLY deal, LGND has a research program which looks at combining a LLY SERM (I believe that they have a second generation SERM that is better than Evista) with a LGND rexinoid (I think that LGND's second generation rexinoids, LGD1268 or LGD1324 are stronger than Targretin) to target cancer (and virtually everyone suspects that it is breast cancer). In animal models, rexinoids and SERMs have shown activity for both treatment and prevention of breast cancer as monothery and in combination (and they synergize when used in combination). LLY's Evista (Raloxifene) and ZEN's Tamoxifen are SERMs that are going head to head in breast cancer prevention trials and LGND's rexinoids synergize with both in animal models and Panretin has shown utility in combination with Tamoxifen in Phase I trials and LGND just announce phase II trails with Targetin, including Tamoxifen resistant tumors as well as adding Targretin to Tamoxifen in advanced cases.